Cardiovascular diseases and chronic obstructive pulmonary disease frequently coexist due to shared pathophysiological mechanisms, requiring integrated management and careful pharmacological selection.
This review emphasizes the high prevalence of COPD in CVD patients and supports the safe use of cardioselective beta-blockers and the preference for ARBs over ACE inhibitors in this comorbid population.
Due to the global aging of the population, the deteriorating ecology and lifestyle changes, patients with isolated cardiovascular diseases (CVD) are becoming less common, and the portrait of a comorbid patient comes first in the structure of patients with CVD. Among a number of diseases complicating and concomitant with cardiovascular, a special place is occupied by chronic obstructive pulmonary disease (COPD). The prevalence of COPD among CVD patients can reach 60%. Many of the pathophysiological mechanisms underlying COPD can increase the risk of cardiovascular disease and vice versa. The most common cases of COPD are arterial hypertension, coronary heart disease, heart failure, and atrial fibrillation. Given the close relationship between COPD and CVD, it is clear that treatment for one condition can affect another. This review discusses current positions about the influence of both groups of diseases on each other, and also observes the effects of drug therapy of both diseases.
Ambatiello et al. (Fri,) conducted a review in Cardiovascular diseases and chronic obstructive pulmonary disease. Pharmacological therapy (cardioselective beta-blockers, RAAS inhibitors, statins) was evaluated. Cardiovascular diseases and chronic obstructive pulmonary disease frequently coexist due to shared pathophysiological mechanisms, requiring integrated management and careful pharmacological selection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: